CareDx Sells Lab Products Business for $170M, Q1 Revenue Rises 39%
CareDx agreed to sell its Lab Products business to EuroBio Scientific for $170 million in cash, including transition services and perpetual North American distribution rights for post-transplant monitoring IVD tests. In Q1 2026, CareDx generated $118 million in revenue, up 39%, with testing services revenue rising 48% to $91 million.
1. Divestment Agreement Details
CareDx has entered a definitive agreement to divest its global Lab Products business to EuroBio Scientific for $170 million in cash. The deal includes at least six months of transition services at EuroBio’s expense and grants CareDx exclusive perpetual rights to distribute post-transplant monitoring IVD tests in North America.
2. Strategic Focus on Core Services
The divestiture simplifies CareDx’s operating model to concentrate on its U.S.-based Precision Medicine Testing Services and Patient and Digital Solutions, which achieved year-over-year revenue growth of 48% and 33%, respectively, in Q1 2026. Proceeds are earmarked for disciplined capital allocation toward high-growth testing services and potential inorganic investments.
3. Preliminary First Quarter Results
CareDx reported approximately $118 million in Q1 revenue, a 39% increase driven by testing service volume of about 54,900 tests, up 17% year-over-year. Testing services revenue reached $91 million, average revenue per test was $1,660, and Patient and Digital Solutions revenue climbed to $16 million.
4. Transaction Timeline and Approvals
The sale, which includes CareDx’s Swedish entity, is subject to regulatory review in Sweden and other customary closing conditions. The companies anticipate closing the transaction by the end of CareDx’s third quarter 2026.